PLASMA CELL MYELOMA

This study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…

This study tested whether adding the drug isatuximab to a standard two-drug therapy (carfilzomib and dexamethasone) helps people with multiple myeloma that has come back or stopped responding to treatment. 302 adults who had already tried 1 to 3 prior treatments took part. The ma…

This study looked at whether patients with multiple myeloma or non-Hodgkin lymphoma could safely skip a drug called tbo-filgrastim after a stem cell transplant. The goal was to see if they could leave the hospital just as quickly without it. 77 adults took part, and researchers c…

This study tested a drug called daratumumab in 49 people with multiple myeloma who were eligible for a stem cell transplant. The goal was to see if daratumumab could help eliminate any remaining cancer cells in the bone marrow after the transplant. While the treatment aims to con…

This early-stage study tested a new drug, SAR442085, in 37 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to find the safest dose and see if the drug could shrink tumors. While the drug aims to control the disease, it…

This study looked at 42 people with multiple myeloma that was still present after a stem cell transplant. It compared continuing lenalidomide alone versus adding two other drugs (ixazomib and dexamethasone) to try to eliminate the remaining cancer. The goal was to see which appro…

This study tested whether giving two drugs—ixazomib and lenalidomide—in an alternating schedule after a stem cell transplant could safely delay the return of multiple myeloma. Thirty patients who had already received a transplant took part. The main goal was to check for side eff…

This study looked at whether people with multiple myeloma can receive their daratumumab (Darzalex Faspro) injections at home instead of at a cancer center. Twenty adults who were already on a monthly daratumumab regimen took part. The main goal was to see if home treatment made p…

This study tested whether a battery-powered drill makes bone marrow biopsies less painful and easier for patients compared to the traditional manual needle. 100 people with plasma cell disorders took part. The goal was to see if the drill improves comfort and biopsy quality.

This study looked at 56 older adults (65+) with multiple myeloma to see if a comprehensive geriatric assessment—a series of questions and tests about physical and mental health—along with blood tests could predict who would have serious side effects from chemotherapy. The goal is…